or Try an Advanced Search...

    Technical Analysis for VERV - Verve Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 6.62 -3.78% -0.26
    VERV closed down 0.43 percent on Tuesday, April 23, 2024, on 71 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical VERV trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish -3.78%
    180 Bearish Setup Bearish Swing Setup -3.78%
    Doji - Bearish? Reversal -3.78%
    Wide Bands Range Expansion -3.78%
    Oversold Stochastic Weakness -3.78%
    Slingshot Bearish Bearish Swing Setup -4.20%
    Wide Bands Range Expansion -4.20%
    Oversold Stochastic Weakness -4.20%
    New 52 Week Closing Low Bearish -0.30%
    Narrow Range Bar Range Contraction -0.30%
    Older End-of-Day Signals for VERV ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 26 minutes ago
    60 Minute Opening Range Breakdown about 4 hours ago
    Down 3% about 4 hours ago
    Bearish 180 Entry about 6 hours ago
    Shooting Star Candlestick Entry about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    VERV Chart by TradingView
    Basic chart:

    Profile

    Verve Therapeutics, Inc. Description

    Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9

    Is VERV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 11 Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
    Apr 6 After a Serious Setback, Is Verve Therapeutics a Buy?
    Apr 5 Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
    Apr 4 Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
    Apr 4 Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
    Apr 3 Verve Therapeutics: An Update On Human CRISPR
    Apr 3 Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
    Apr 3 Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
    Apr 2 Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 2 Verve Falls as Gene-Editing Trial Paused on Safety Issues
    See more VERV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 21.4199
    52 Week Low 6.42
    Average Volume 1,359,841
    200-Day Moving Average 13.32
    50-Day Moving Average 12.03
    20-Day Moving Average 8.77
    10-Day Moving Average 7.20
    Average True Range 0.75
    RSI (14) 24.81
    ADX 42.51
    +DI 14.64
    -DI 37.93
    Chandelier Exit (Long, 3 ATRs) 11.38
    Chandelier Exit (Short, 3 ATRs) 8.67
    Upper Bollinger Bands 13.24
    Lower Bollinger Band 4.30
    Percent B (%b) 0.29
    BandWidth 101.98
    MACD Line -1.62
    MACD Signal Line -1.58
    MACD Histogram -0.0379
    Fundamentals Value
    Market Cap 553.32 Million
    Num Shares 80.4 Million
    EPS -3.08
    Price-to-Earnings (P/E) Ratio -2.23
    Price-to-Sales 130.77
    Price-to-Book 2.06
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.78
    Resistance 3 (R3) 7.86 7.63 7.63
    Resistance 2 (R2) 7.63 7.40 7.60 7.58
    Resistance 1 (R1) 7.26 7.26 7.15 7.18 7.53
    Pivot Point 7.03 7.03 6.98 7.00 7.03
    Support 1 (S1) 6.66 6.80 6.55 6.58 6.23
    Support 2 (S2) 6.43 6.66 6.40 6.18
    Support 3 (S3) 6.06 6.43 6.13
    Support 4 (S4) 5.98